Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2019

Open Access 01-12-2019 | Cervical Cancer | Research

RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer

Authors: Annapurna Pranatharthi, Pavana Thomas, Avinash H. Udayashankar, Chandra Bhavani, Srinag Bangalore Suresh, Sudhir Krishna, Jayashree Thatte, Nirmala Srikantia, Cecil R. Ross, Sweta Srivastava

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2019

Login to get access

Abstract

Background

Radioresistance remains a challenge to the successful treatment of various tumors. Intrinsic factors like alterations in signaling pathways regulate response to radiation. RhoC, which has been shown to modulate several tumor phenotypes has been investigated in this report for its role in radioresistance. In vitro and clinical sample-based studies have been performed to understand its contribution to radiation response in cervical cancer and this is the first report to establish the role of RhoC and its effector ROCK2 in cervical cancer radiation response.

Methods

Biochemical, transcriptomic and immunological approaches including flow cytometry and immunofluorescence were used to understand the role of RhoC and ROCK2. RhoC variants, siRNA and chemical inhibitors were used to alter the function of RhoC and ROCK2. Transcriptomic profiling was performed to understand the gene expression pattern of the cells. Live sorting using an intracellular antigen has been developed to isolate the cells for transcriptomic studies.

Results

Enhanced expression of RhoC conferred radioprotection on the tumor cells while inhibition of RhoC resulted in sensitization of cells to radiation. The RhoC overexpressing cells had a better DNA repair machinery as observed using transcriptomic analysis. Similarly, overexpression of ROCK2, protected tumor cells against radiation while its inhibition increased radiosensitivity in vitro. Further investigations revealed that ROCK2 inhibition abolished the radioresistance phenotype, conferred by RhoC on SiHa cells, confirming that it is a downstream effector of RhoC in this context. Additionally, transcriptional analysis of the live sorted ROCK2 high and ROCK2 low expressing SiHa cells revealed an upregulation of the DNA repair pathway proteins. Consequently, inhibition of ROCK2 resulted in reduced expression of pH2Ax and MRN complex proteins, critical to repair of double strand breaks. Clinical sample-based studies also demonstrated that ROCK2 inhibition sensitizes tumor cells to irradiation.

Conclusions

Our data primarily indicates that RhoC and ROCK2 signaling is important for the radioresistance phenotype in cervical cancer tumor cells and is regulated via association of ROCK2 with the proteins of DNA repair pathway involving pH2Ax, MRE11 and RAD50 proteins, partly offering insights into the mechanism of radioresistance in tumor cells. These findings highlight RhoC-ROCK2 signaling involvement in DNA repair and urge the need for development of these molecules as targets to alleviate the non-responsiveness of cervical cancer tumor cells to irradiation treatment.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2012;65(2):87–108.CrossRef
2.
3.
Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2017;37(4):278–85.CrossRef
4.
Endo D, Todo Y, Okamoto K, Minobe S, Kato H, Nishiyama N. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. J Gynecol Oncol. 2015;26(1):12–8.CrossRefPubMedPubMedCentral
5.
Kim TE, Park BJ, Kwack HS, Kwon JY, Kim JH, Yoon SC. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation. J Obstet Gynaecol Res. 2012;38(11):1315–20.CrossRefPubMed
6.
Kudaka W, Nagai Y, Toita T, et al. Long-term results and prognostic factors in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study. Int J Clin Oncol. 2013;18(5):916–21.CrossRefPubMed
7.
Toulany M, Dittmann K, Fehrenbacher B, Schaller M, Baumann M, Rodemann HP. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. DNA Repair (Amst). 2008;7(10):1746–56.CrossRef
8.
Schaue D, McBride WH. Counteracting tumor radioresistance by targeting DNA repair. Mol Cancer Ther. 2005;4(10):1548–50.CrossRefPubMed
9.
10.
Vega FM, Ridley AJ. The RhoB small GTPase in physiology and disease. Small GTPases. 2016;9(5):1–10.
11.
Chen W, Delongchamps NB, Mao K, et al. High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. Oncol Lett. 2016;11(2):1375–81.CrossRefPubMed
12.
Duan JT, Wang XM, Zhang SQ, Zhao GJ. Effect of RhoA gene silencing on proliferation and migration of gastric MGC-803 cells. Int J Clin Exp Med. 2015;8(8):14410–5.PubMedPubMedCentral
13.
Huang M, Prendergast GC. RhoB in cancer suppression. Histol Histopathol. 2006;21(2):213–8.PubMed
14.
15.
Kawata H, Kamiakito T, Omoto Y, Miyazaki C, Hozumi Y, Tanaka A. RhoC upregulation is correlated with reduced E-cadherin in human breast cancer specimens after chemotherapy and in human breast cancer MCF-7 cells. Horm Cancer. 2014;5(6):414–23.CrossRefPubMed
16.
Hoeppner LH, Sinha S, Wang Y, et al. RhoC maintains vascular homeostasis by regulating VEGF-induced signaling in endothelial cells. J Cell Sci. 2015;128(19):3556–68.CrossRefPubMedPubMedCentral
17.
Guan X, Chen S, Zhao Y. The role of RhoC in malignant tumor invasion, metastasis and targeted therapy. Histol Histopathol. 2017;33(3):255–60.PubMed
18.
Egami Y, Kawai K, Araki N. RhoC regulates the actin remodeling required for phagosome formation during FcgammaR-mediated phagocytosis. J Cell Sci. 2017;130(24):4168–79.CrossRefPubMed
19.
20.
21.
Sahai E, Olson MF, Marshall CJ. Cross-talk between Ras and rho signalling pathways in transformation favours proliferation and increased motility. EMBO J. 2001;20(4):755–66.CrossRefPubMedPubMedCentral
22.
Wu M, Wu ZF, Kumar-Sinha C, Chinnaiyan A, Merajver SD. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat. 2004;84(1):3–12.CrossRefPubMed
23.
Sang XB, Sun KX, Wang LL, et al. Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis. Oncol Rep. 2016;36(6):3267–74.CrossRefPubMed
24.
Kondo T, Sentani K, Oue N, Yoshida K, Nakayama H, Yasui W. Expression of RHOC is associated with metastasis of gastric carcinomas. Pathobiology. 2004;71(1):19–25.CrossRefPubMed
25.
Paul D, Chanukuppa V, Reddy PJ, et al. Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma. J Proteome. 2016;138:95–105.CrossRef
26.
27.
Islam M, Sharma S, Teknos TN. RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT3. PLoS One. 2014;9(2):e88527.CrossRefPubMedPubMedCentral
28.
Srivastava S, Ramdass B, Nagarajan S, Rehman M, Mukherjee G, Krishna S. Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. Br J Cancer. 2010;102(1):196–205.CrossRefPubMed
29.
Hakem A, Sanchez-Sweatman O, You-Ten A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev. 2005;19(17):1974–9.CrossRefPubMedPubMedCentral
30.
Sadok A, McCarthy A, Caldwell J, et al. Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Res. 2015;75(11):2272–84.CrossRefPubMed
31.
Kamai T, Tsujii T, Arai K, et al. Significant association of rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003;9(7):2632–41.PubMed
32.
Mertsch S, Thanos S. Opposing signaling of ROCK1 and ROCK2 determines the switching of substrate specificity and the mode of migration of glioblastoma cells. Mol Neurobiol. 2013;49(2):900–15.CrossRefPubMedPubMedCentral
33.
Hanashiro K, Brancaccio M, Fukasawa K. Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification. Oncogene. 2011;30(19):2188–97.CrossRefPubMed
34.
Ling H, Hanashiro K, Luong TH, Benavides L, Fukasawa K. Functional relationship among PLK2, PLK4 and ROCK2 to induce centrosome amplification. Cell Cycle. 2015;14(4):544–53.CrossRefPubMedPubMedCentral
35.
Ma Z, Kanai M, Kawamura K, Kaibuchi K, Ye K, Fukasawa K. Interaction between ROCK II and nucleophosmin/B23 in the regulation of centrosome duplication. Mol Cell Biol. 2006;26(23):9016–34.CrossRefPubMedPubMedCentral
36.
Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103(1):127–40.CrossRefPubMed
37.
38.
Britton S, Coates J, Jackson SP. A new method for high-resolution imaging of Ku foci to decipher mechanisms of DNA double-strand break repair. J Cell Biol. 2013;202(3):579–95.CrossRefPubMedPubMedCentral
39.
Ramdass B, Maliekal TT, Lakshmi S, et al. Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol. 2007;104(2):352–61.CrossRefPubMed
40.
Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res. 2015;43(W1):W566–70.CrossRefPubMedPubMedCentral
41.
Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):3.CrossRef
42.
43.
de Jager M, van Noort J, van Gent DC, Dekker C, Kanaar R, Wyman C. Human Rad50/Mre11 is a flexible complex that can tether DNA ends. Mol Cell. 2001;8(5):1129–35.CrossRefPubMed
44.
Hopfner KP, Karcher A, Craig L, Woo TT, Carney JP, Tainer JA. Structural biochemistry and interaction architecture of the DNA double-strand break repair Mre11 nuclease and Rad50-ATPase. Cell. 2001;105(4):473–85.CrossRefPubMed
45.
Olive PL. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol. 2004;75:355–73.CrossRefPubMed
46.
47.
Chaturvedi LS, Marsh HM, Basson MD. Role of RhoA and its effectors ROCK and mDia1 in the modulation of deformation-induced FAK, ERK, p38, and MLC motogenic signals in human Caco-2 intestinal epithelial cells. Am J Physiol Cell Physiol. 2011;301(5):C1224–38.CrossRefPubMedPubMedCentral
48.
Wang HF, Takenaka K, Nakanishi A, Miki Y. BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2. Cancer Res. 2010;71(1):68–77.CrossRefPubMed
49.
Liu T, Yu X, Li G, et al. Rock2 regulates Cdc25A through ubiquitin proteasome system in hepatocellular carcinoma cells. Exp Cell Res. 2012;318(16):1994–2003.CrossRefPubMed
50.
Yu Z, Liu M, Fu P, Xie M, Wang W, Luo X. ROCK inhibition with Y27632 promotes the proliferation and cell cycle progression of cultured astrocyte from spinal cord. Neurochem Int. 2012;61(7):1114–20.CrossRefPubMed
51.
Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996;392(2):189–93.CrossRefPubMed
52.
Chatterjee S, Lesniak WG, Gabrielson M, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7(9):10215–27.CrossRefPubMedPubMedCentral
53.
Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 1994;9(9):2663–74.PubMed
54.
Hellebust A, Richards-Kortum R. Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics. Nanomedicine (Lond). 2012;7(3):429–45.CrossRef
55.
McCormick A, Donoghue P, Dixon M, et al. Ovarian Cancers Harbor defects in nonhomologous end joining resulting in resistance to Rucaparib. Clin Cancer Res. 2016;23(8):2050–60.CrossRefPubMedPubMedCentral
56.
Zucchini C, Manara MC, Pinca RS, et al. CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene. 2013;33(15):1912–21.CrossRefPubMed
57.
Saito S, Yamaguchi H, Higashimoto Y, et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem. 2003;278(39):37536–44.CrossRefPubMed
58.
Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. 2003;23(16):5706–15.CrossRefPubMedPubMedCentral
59.
Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39–85.CrossRefPubMed
60.
Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol. 2003;81(3):123–9.CrossRefPubMed
61.
Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo. 2008;22(3):305–9.PubMed
62.
63.
Okorokov AL, Rubbi CP, Metcalfe S, Milner J. The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage. Oncogene. 2002;21(3):356–67.CrossRefPubMed
64.
Wang L, Wang M, Wang S, et al. Actin polymerization negatively regulates p53 function by impairing its nuclear import in response to DNA damage. PLoS One. 2013;8(4):e60179.CrossRefPubMedPubMedCentral
65.
Hurst V, Shimada K, Gasser SM. Nuclear actin and actin-binding proteins in DNA repair. Trends Cell Biol. 2019;29(6):462–76.CrossRefPubMed
66.
Menon V, Povirk L. Involvement of p53 in the repair of DNA double strand breaks: multifaceted roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ). Subcell Biochem. 2014;85:321–36.CrossRefPubMedPubMedCentral
67.
Al Rashid ST, Dellaire G, Cuddihy A, et al. Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res. 2005;65(23):10810–21.CrossRefPubMed
68.
Freudlsperger C, Horn D, Weissfuss S, et al. Phosphorylation of AKT (Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. Int J Cancer. 2014;136(12):2775–85.CrossRefPubMed
69.
Cho HJ, Oh YJ, Han SH, et al. Cdk1 protein-mediated phosphorylation of receptor-associated protein 80 (RAP80) serine 677 modulates DNA damage-induced G2/M checkpoint and cell survival. J Biol Chem. 2013;288(6):3768–76.CrossRefPubMed
70.
Du W, Zhou Y, Pike S, Pang Q. NPM phosphorylation stimulates Cdk1, overrides G2/M checkpoint and increases leukemic blasts in mice. Carcinogenesis. 2010;31(2):302–10.CrossRefPubMed
71.
Enomoto M, Goto H, Tomono Y, et al. Novel positive feedback loop between Cdk1 and Chk1 in the nucleus during G2/M transition. J Biol Chem. 2009;284(49):34223–30.CrossRefPubMedPubMedCentral
72.
Van Horn RD, Chu S, Fan L, et al. Cdk1 activity is required for mitotic activation of aurora A during G2/M transition of human cells. J Biol Chem. 2010;285(28):21849–57.CrossRefPubMedPubMedCentral
73.
Kumper S, Mardakheh FK, McCarthy A, et al. Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. Elife. 2016;5:e12994.CrossRefPubMed
74.
Timofeev O, Cizmecioglu O, Settele F, Kempf T, Hoffmann I. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J Biol Chem. 2010;285(22):16978–90.CrossRefPubMedPubMedCentral
75.
Wang HF, Takenaka K, Nakanishi A, Miki Y. BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the rho effector kinase ROCK2. Cancer Res. 2011;71(1):68–77.CrossRefPubMed
76.
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–68.CrossRef
77.
McLaughlin N, Annabi B, Bouzeghrane M, et al. The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (−)-epigallocatechin-3-gallate. Brain Res. 2006;1071(1):1–9.CrossRefPubMed
78.
Kleer CG, Zhang Y, Pan Q, et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. 2004;6(1):R110–5.CrossRefPubMed
79.
Kleer CG, Griffith KA, Sabel MS, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat. 2005;93(2):101–10.CrossRefPubMed
80.
Ma W, Sze KM, Chan LK, et al. RhoE/ROCK2 regulates chemoresistance through NF-kappaB/IL-6/ STAT3 signaling in hepatocellular carcinoma. Oncotarget. 2016;7(27):41445–59.PubMedPubMedCentral
81.
Xu B, Kastan MB. Analyzing cell cycle checkpoints after ionizing radiation. Methods Mol Biol. 2004;281:283–92.PubMed
82.
Sedelnikova OA, Pilch DR, Redon C, Bonner WM. Histone H2AX in DNA damage and repair. Cancer Biol Ther. 2003;2(3):233–5.CrossRefPubMed
83.
Tanaka T, Nishimura D, Wu RC, et al. Nuclear rho kinase, ROCK2, targets p300 acetyltransferase. J Biol Chem. 2006;281(22):15320–9.CrossRefPubMed
84.
Wang HF, Takenaka K, Nakanishi A, Miki Y. BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the rho effector kinase ROCK2. Cancer Res. 2010;71(1):68–77.CrossRefPubMed
85.
Zhou Z, Meng Y, Asrar S, Todorovski Z, Jia Z. A critical role of rho-kinase ROCK2 in the regulation of spine and synaptic function. Neuropharmacology. 2009;56(1):81–9.CrossRefPubMed
86.
Zhang Y, Li X, Qi J, et al. Rock2 controls TGFbeta signaling and inhibits mesoderm induction in zebrafish embryos. J Cell Sci. 2009;122(Pt 13):2197–207.CrossRefPubMed
87.
Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology. 2009;49(5):1583–94.CrossRefPubMed
88.
89.
Chardin P, Boquet P, Madaule P, Popoff MR, Rubin EJ, Gill DM. The mammalian G protein rhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in Vero cells. EMBO J. 1989;8(4):1087–92.CrossRefPubMedPubMedCentral
90.
Ridley AJ. RhoA, RhoB and RhoC have different roles in cancer cell migration. J Microsc. 2013;251(3):242–9.CrossRefPubMed
91.
Dubash AD, Guilluy C, Srougi MC, Boulter E, Burridge K, Garcia-Mata R. The small GTPase RhoA localizes to the nucleus and is activated by Net1 and DNA damage signals. PLoS One. 2011;6(2):e17380.CrossRefPubMedPubMedCentral
92.
Srivastava S, Krishna S. Cancer stem cells: an approach to identify newer therapeutic targets. J Stem Cells. 2009;4(2):123–31.PubMed
93.
Lopez J, Poitevin A, Mendoza-Martinez V, Perez-Plasencia C, Garcia-Carranca A. Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer. 2012;12(2012):48.CrossRefPubMedPubMedCentral
94.
Pavlopoulou A, Oktay Y, Vougas K, Louka M, Vorgias CE, Georgakilas AG. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells. Cancer Lett. 2016;380(2):485–93.CrossRefPubMed
95.
Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. Int J Mol Sci. 2017;18(12):2574.CrossRefPubMedCentral
96.
Lee SY, Jeong EK, Ju MK, et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 2017;16(1):10.CrossRefPubMedPubMedCentral
97.
Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001;3(4):346–52.CrossRefPubMed
98.
Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breard J. Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med. 2005;201(3):465–71.CrossRefPubMedPubMedCentral
99.
Jenkins SV, Nima ZA, Vang KB, et al. Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems. NPJ Precis Oncol. 2018;1(1):27.CrossRef
Metadata
Title
RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer
Authors
Annapurna Pranatharthi
Pavana Thomas
Avinash H. Udayashankar
Chandra Bhavani
Srinag Bangalore Suresh
Sudhir Krishna
Jayashree Thatte
Nirmala Srikantia
Cecil R. Ross
Sweta Srivastava
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2019
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-019-1385-7

Other articles of this Issue 1/2019

Journal of Experimental & Clinical Cancer Research 1/2019 Go to the issue

Research

FAM83H is involved in stabilization of β-catenin and progression of osteosarcomas

Research

Nuclear FAM289-Galectin-1 interaction controls FAM289-mediated tumor promotion in malignant glioma

Research

Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer

Research

Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6

Research

Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits

Research

P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits